FDA Approves First-in-Class Drug for Follicular Lymphoma

The first-in-class bispecific antibody mosunetuzumab-axgb (Lunsumio) has been granted an accelerated approval for use in relapsed or refractory follicular lymphoma.
FDA Approvals

source https://www.medscape.com/viewarticle/986083?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost